Scilex Holding (SCLX) Net Margin Growth (1y) (2023 - 2026)

Scilex Holding (SCLX) Net Margin Growth (1y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin Growth (1y) (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 1,568.00
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -2,848.00
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn -501.00
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 29,782.00
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -5,859.00
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -12.00
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 931.00
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Scilex Holding 54.30 Mn -95.62 Mn 4.15 Mn 1,846.00

Historic Data

Download Data
DateValue
Mar 31, 2026 1,846.00
Dec 31, 2025 -58,108.00
Sep 30, 2025 -240,553.00
Jun 30, 2025 -64,008.00
Mar 31, 2025 -29,763.00
Dec 31, 2024 5,591.00
Sep 30, 2024 84,115.00
Jun 30, 2024 -1,778.00
Mar 31, 2024 6,665.00
Dec 31, 2023 -892.00
Sep 30, 2023 -106,053.00
Jun 30, 2023 1,325.00
Mar 31, 2023 -15,640.00